Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Acceleron Pharma (XLRN) stock just cleared that benchmark with an upgrade from 64 to 83.


When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.

This exclusive rating from Investor’s Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in our database.

History reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they begin their biggest price moves.

See How IBD Helps You Make More Money In Stocks

Is Acceleron Pharma Stock A Buy?

Acceleron Pharma stock is within a buy range after moving past a 146.25 entry in a consolidation. Once a stock moves 5% or higher beyond the initial entry, it’s considered out of buy range. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”


The biotech firm reported negative growth for both sales and earnings last quarter.

Acceleron Pharma stock holds the No. 84 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) and Alkermes (ALKS) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button